Sara M Tolaney

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint New HER2-Positive Targeting Agents in Clinical Practice
    Sara Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1257, Boston, MA, 02215, USA
    Curr Oncol Rep 16:359. 2014
  2. ncbi request reprint Follow-up care of patients with breast cancer
    Sara M Tolaney
    Dana Farber Cancer Institute, 44 Binney Street, Mayer 2, Boston, MA 02115, USA
    Breast 16:S45-50. 2007
  3. ncbi request reprint Sarcoidosis mimicking metastatic breast cancer
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Breast Cancer 7:804-10. 2007
  4. doi request reprint Lymphopenia associated with adjuvant anthracycline/ taxane regimens
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Breast Cancer 8:352-6. 2008
  5. ncbi request reprint Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 24:5330-1. 2006
  6. doi request reprint Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice
    Kathryn J Ruddy
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA
    Breast Cancer Res Treat 141:421-7. 2013
  7. doi request reprint A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
    Joyce F Liu
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Eur J Cancer 49:2972-8. 2013
  8. doi request reprint Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction
    Kari Joanne Kansal
    Brigham and Women s Hopspital, Boston, MA, USA
    Breast Cancer Res Treat 141:255-9. 2013
  9. ncbi request reprint Mechanisms of trastuzumab resistance in breast cancer
    Sara M Tolaney
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Anticancer Agents Med Chem 9:348-55. 2009
  10. pmc Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer
    Judy E Garber
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Natl Cancer Inst 102:942-9. 2010

Detail Information

Publications10

  1. doi request reprint New HER2-Positive Targeting Agents in Clinical Practice
    Sara Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1257, Boston, MA, 02215, USA
    Curr Oncol Rep 16:359. 2014
    ..These exciting advances in drug development for HER2-positive breast cancer have also led to many challenges, including how to optimally sequence and combine HER2-targeted agents. ..
  2. ncbi request reprint Follow-up care of patients with breast cancer
    Sara M Tolaney
    Dana Farber Cancer Institute, 44 Binney Street, Mayer 2, Boston, MA 02115, USA
    Breast 16:S45-50. 2007
    ..With the growing number of breast cancer survivors, further studies should be undertaken to study the cost-effectiveness of surveillance strategies...
  3. ncbi request reprint Sarcoidosis mimicking metastatic breast cancer
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Breast Cancer 7:804-10. 2007
    ..We describe 3 patients who presented with locally advanced breast cancer and who were found to have pulmonary findings for metastatic disease that were proven upon biopsy to be consistent with sarcoidosis...
  4. doi request reprint Lymphopenia associated with adjuvant anthracycline/ taxane regimens
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Breast Cancer 8:352-6. 2008
    ....
  5. ncbi request reprint Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 24:5330-1. 2006
  6. doi request reprint Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice
    Kathryn J Ruddy
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA
    Breast Cancer Res Treat 141:421-7. 2013
    ....
  7. doi request reprint A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
    Joyce F Liu
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Eur J Cancer 49:2972-8. 2013
    ..We investigated the toxicities and recommended phase 2 dosing (RP2D) of the combination of cediranib, a multitargeted inhibitor of vascular endothelial growth factor receptor (VEGFR)-1/2/3 and olaparib, a PARP-inhibitor (NCT01116648)...
  8. doi request reprint Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction
    Kari Joanne Kansal
    Brigham and Women s Hopspital, Boston, MA, USA
    Breast Cancer Res Treat 141:255-9. 2013
    ..As larger data sets become available with the use of neoadjuvant bevacizumab with mastectomy, further refinement may be necessary. ..
  9. ncbi request reprint Mechanisms of trastuzumab resistance in breast cancer
    Sara M Tolaney
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Anticancer Agents Med Chem 9:348-55. 2009
    ..In this review, we discuss the mechanisms of antitumor activity of trastuzumab, potential mechanisms contributing to its resistance, and novel therapeutic agents that may provide a means to overcome trastuzumab resistance...
  10. pmc Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer
    Judy E Garber
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Natl Cancer Inst 102:942-9. 2010
    ..We investigated whether FVL was associated with TE risk in women with early-stage breast cancer who took adjuvant tamoxifen...